In the BioHarmony Drug Report Database
Obinutuzumab
Gazyva, Gazyvaro (obinutuzumab) is an antibody pharmaceutical. Obinutuzumab was first approved as Gazyva on 2013-11-01. It is used to treat follicular lymphoma and lymphoid leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against B-lymphocyte antigen CD20.
Trade Name
|
Gazyvaro |
|---|---|
Common Name
|
obinutuzumab |
ChEMBL ID
|
CHEMBL1743048 |
Indication
|
b-cell chronic lymphocytic leukemia, follicular lymphoma, lymphoid leukemia |
Drug Class
|
Monoclonal antibodies: humanized, tumors as target |
Image (chem structure or protein)
